DNA Methylation and the Mechanisms of CDKN2A Inactivation in Transitional Cell Carcinoma of the Urinary Bladder

Akao, 1997, A high prevalence of functional inactivation by methylation modification of p16INK4A/CDKN2/MTS1 gene in primary urothelial cancers, Jpn J Cancer Res, 88, 1078, 10.1111/j.1349-7006.1997.tb00332.x An, 1996, Frequent allele loss on 9p21-22 defines a smallest common region in the vicinity of the CDKN2 gene in sporadic breast cancer, Genes Chromosomes Cancer, 17, 14, 10.1002/(SICI)1098-2264(199609)17:1<14::AID-GCC3>3.0.CO;2-5 Balazs, 1997, Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization, Genes Chromosomes Cancer, 19, 84, 10.1002/(SICI)1098-2264(199706)19:2<84::AID-GCC3>3.0.CO;2-W Baud, 1999, p16 involvement in primary bladder tumors: Analysis of deletions and mutations, Int J Oncol, 14, 441 Bender, 1998, Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines, Cancer Res, 58, 95 Cairns, 1998, A comparison between microsatellite and quantitative PCR analyses to detect frequent p16 copy number changes in primary bladder tumors, Clin Cancer Res, 4, 441 Chen, 1998, DNA hypomethylation leads to elevated mutation rates, Nature, 395, 89, 10.1038/25779 Czerniak, 1999, Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: Implication for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer, Oncogene, 18, 1185, 10.1038/sj.onc.1202385 Ehrlich, 2000, DNA hypomethylation and cancer, DNA alterations in cancer, 273 Esrig, 1994, Accumulation of nuclear p53 and tumor progression in bladder cancer, N Engl J Med, 331, 1259, 10.1056/NEJM199411103311903 Florl, 1999, DNA methylation and expression of L1 LINE and HERV-K provirus sequences in urothelial and renal cell carcinoma, Br J Cancer, 80, 1312, 10.1038/sj.bjc.6690524 Gonzalez-Zulueta, 1995, Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing, Cancer Res, 55, 4531 Gonzalgo, 1998, The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines, Cancer Res, 58, 1245 Grim, 1997, Adenovirus-mediated delivery of p16 to p16-deficient human bladder cancer cells confers chemoresistance to cisplatin and paclitaxel, Clin Cancer Res, 3, 2415 Hartmann, 1999, Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma, Am J Pathol, 154, 721, 10.1016/S0002-9440(10)65318-7 Herman, 1996, Methylation-specific PCR: A novel assay for methylation status of CpG islands, Proc Natl Acad Sci USA, 93, 9821, 10.1073/pnas.93.18.9821 Jeanpierre, 1993, An embryonic-like methylation pattern of classical satellite DNA is observed in ICF syndrome, Hum Mol Genet, 2, 731, 10.1093/hmg/2.6.731 Jung, 1999, Chromosome 9 monosomy by fluorescence in situ hybridization of bladder irrigation specimens is predictive of tumor recurrence, J Urol, 162, 1900, 10.1016/S0022-5347(05)68064-0 Jürgens, 1996, Hypomethylation of L1 LINE sequences prevailing in human urothelial carcinoma, Cancer Res, 56, 5698 Kai, 1995, Infrequent somatic mutation of the MTS1 gene in primary bladder carcinomas, Jpn J Cancer Res, 86, 249, 10.1111/j.1349-7006.1995.tb03047.x Kallioniemi, 1995, Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization, Genes Chromosomes Cancer, 12, 213, 10.1002/gcc.2870120309 Kamb, 1994, A cell cycle regulator potentially involved in genesis of many tumor types, Science, 264, 436, 10.1126/science.8153634 Kazazian, 1998, The impact of L1 retrotransposons on the human genome, Nat Genet, 19, 19, 10.1038/ng0598-19 Knowles, 1999, The genetics of transitional cell carcinoma: Progress and potential clinical application, BJU Int, 84, 412, 10.1046/j.1464-410x.1999.00217.x Markl, 1998, Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer, Cancer Res, 58, 5348 Merlo, 1995, 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers, Nat Med, 1, 686, 10.1038/nm0795-686 Orlow, 1995, Deletion of the p16 and p15 genes in human bladder tumors, J Natl Cancer Inst, 87, 1524, 10.1093/jnci/87.20.1524 Orlow, 1999, Deletions of the INK4A gene in superficial bladder tumors, Am J Pathol, 155, 105, 10.1016/S0002-9440(10)65105-X Orntoft, 1998, Molecular alterations in bladder cancer, Urol Res, 26, 223, 10.1007/s002400050050 Packenham, 1995, Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors, Mol Carcinog, 14, 147, 10.1002/mc.2940140303 Presti, 1991, Molecular genetic alterations in superficial and locally advanced human bladder cancer, Cancer Res, 51, 5405 Quelle, 1995, Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest, Cell, 83, 993, 10.1016/0092-8674(95)90214-7 Rein, 1998, Identifying 5-methylcytosine and related modifications in DNA genomes, Nucleic Acids Res, 26, 2255, 10.1093/nar/26.10.2255 Ruas, 1998, The p16INK4A/CDKN2A tumor suppressor and its relatives, Biochim Biophys Acta, 1378, F115 Schulz, 1998, DNA methylation in urological malignancies, Int J Oncol, 13, 151 Williamson, 1995, p16 (CDKN2) is a major deletion target at 9p21 in bladder cancer, Hum Mol Genet, 4, 1569, 10.1093/hmg/4.9.1569 Xu, 1999, Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene, Nature, 402, 187, 10.1038/46052 Yeager, 1998, Overcoming cellular senescence in human cancer pathogenesis, Genes Dev, 12, 163, 10.1101/gad.12.2.163 Zhao, 1999, Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa, Cancer Res, 59, 4658